Resources

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2’s Most Recent Studies

Validated Tumor Cell Lines

Navigating Project Optimus with TD2

Epigenetic-Based Combinatorial Therapy is Synergistic in KRAS/LKB1 Mutant Non-Small Cell Lung Cancers

Integrating PDX GBM In Vivo Models with Patient History and Whole Exome Sequencing: Advancing Relevance and Precision in Preclinical Studies

Flow cytometry evaluation of cell cycle arrest in A549 human non-small cell lung cancer cells and tumors following treatment with cell cycle inhibitors: A multifaceted approach to targeting cancer

Immunophenotyping Pig Immune Cells by Flow Cytometry: A Powerful Tool for Pharmacology and Toxicology Studies

Flow Cytometry Application in Water Microbiology: Testing Bacterial Content in Water

Flow Cytometry Processing and Analysis of Tumor Specimens: Testing Viability and Staining Post Shipping

Flow Cytometry Based Assessment of Innate Immune Function Using Phagocytosis and Reactive Oxygen Species Measurement

Measurement of Cytokine mRNA Expression by Flow Cytometry Using the Branched DNA Technology

10-Color Flow Cytometry Panels for the Evaluation of T Cell Subsets Such as TH Subsets, T Cell Activation, and T Regulatory Cells for Application in Clinical Trials

The Advantages of Fluorescent Barcoding of Human Cells Using Flow Cytometry for High Throughput Testing With an Application For Human Clinical Trials

The Activation Profiling of Stat in Human Whole Blood Samples By Flow Cytometry With an Application for Human Clinical Trials

Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens

Climbing the Mountain: Current Challenges in Early Phase Oncology Clinical Trials

The Significance of Preclinical Evaluation in CAR T-cell Therapy for Solid and Hematologic Tumors

The Importance of Metabolic and Proteomic Analyses in Identifying Treatment Pathways for Cancer Patients

E-Book: Using the Diet Induced Obese Mouse Model for Modern Cancer Research

A Dual-specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis

Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers

Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to Induce Tumor Regressions

SITC 2023 Poster: Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice

Navigating the Regulatory Process to Accelerate Drug Development

Metabolomics Sample Data Analysis Report

Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice

Overcoming Oncology Clinical Trial Challenges, a discussion with Dr. Alan Miller

Avoiding Delays in Early-Phase Oncology Clinical Trials

Improving Oncology Clinical Trial Success – the Importance of Investigator and Site Relationships

Leading the way in defining a new Immunotherapy Response Score (IRS) to predict checkpoint inhibitor benefit

Early Phase Oncology Trial Designs Phase I Strategies Tailored for Success

CAR T-cell Program Development: Key Considerations

TD2 Immuno-Oncology

Executive Interview with TD2

TD2 Clinical Capabilities

Partner with an Experienced, Scientifically-Driven Cncology CRO

Cell Therapy at TD2

CAR-T Summit Tech Slam

Clinical Trial Highlight

Glioblastoma Capabilities

Biomarkers and the utility of proteomics for dose optimization and confirmation of target engagement

The Dynamic Trial Design

Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response

Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers

Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…

Exploring the Effects of Microbiome in Precision Oncology Therapeutic Development

Improving Cancer Trial Recruitment With Advanced Analytics and Prospective Data

Data Insights: Identifying Early Signs of Safety and Efficacy in Oncology Clinical Trials

The Dynamic Trial: Is It the Right Option for You?

Efficient Data Management: One Way to Expedite the Clinical Development Process

Many Drugs Don’t Move Past Phase I. Will Yours?

The Quick-Start Guide to Clinical Strategy

6 Signs You Need a New CRO for Your Preclinical Research

The Trends Behind Successful Cancer Treatments

Technology and Next-Generation Oncology Trials

STAY IN TOUCH

Get free tips, tools and resources by subscribing to the TD2 newsletter.

Skip to content